Induction of TGF-β1 synthesis in D-glucose primed human proximal tubular cells by IL-1β and TNFα  by Phillips, Aled O. et al.
Kidney International, Vol. 50 (1996), pp. 1546—1554
Induction of TGF-/31 synthesis in D-glucose primed human
proximal tubular cells by IL-113 and TNFa
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and JOHN D. WILLIAMS
Institute of Nephrology, University of Wales College of Medicine, C'ardi Royal infirmary, Newport Road, Cardiff Wales, United Kingdom
Induction of TGF-pl synthesis in D-glucose primed human proximal
tubular cells by IL-Ill and TNFs. The aim of the present study was to
examine whether the induction of TGF-f31 synthesis by the pro-inflam-
matory macrophage derived cytokines, IL-i/I or TNFa, was modified by
alterations in D-glucose concentrations. Stimulation of growth arrested
HPTC with IL-i/I or TNFa resulted in increased expression of TGF-/I1
mRNA. The transcript was demonstrable 60 minutes after the addition of
IL-i/I, and apparent steady-state mRNA levels were achieved after six
hours. Following stimulation with TNFa, TGF-/I1 mRNA was detectable
after 15 minutes and reached steady state levels by two hours. Quantitative
RT-PCR revealed that following six hours stimulation with either IL-Ill or
TNFa (both at I nglml), there was no difference in the absolute amount
of TGF-[31 mRNA induced by these two stimuli (14.8 5.6 vs. 19.7 4.9
pM). Despite induction of TGF-j31 mRNA following stimulation with
IL-Ill or TNFa, neither stimulus increased TGF-/I1 protein synthesis or
release. Pre-exposure of HPTC to 25 mivi D-glucose for 48 hours and
subsequent stimulation with IL-i/I resulted in the secretion of latent
TGF-/Il in both a time and dose dependent manner. This effect was not
apparent following TNFa stimulation of D-glueose primed HPTC. Stim-
ulation of TGF-/I1 synthesis by IL-I/I in D-glueose primed cells was
inhibited by cycloheximide hut not by actinomyein-D. Examination of
D-glueose induced TGF-/I1 mRNA revealed that IL-ill, but not TNFa,
increased the stability of the D-glucose induced transcript. These results
demonstrate that the interaction of D-glucose and IL-I/I lead to secretion
of TGF-f31 by HPTC. In contrast, such an interaction was not demonstra-
ble between D-glueose and TNFa. This may he explained by the ability of
IL-l/3 to stabilize D-glueosc-indueed TGF-/I1 mRNA.
Recent epidemiological evidence indicates that hyperglycemia
plays an important role in the development of the microvascular
complications of diabetes mellitus [1—5]. Hyperglycemia and poor
diabetic control alone, however, are clearly insufficient to initiate
diabetic nephropathy. It is therefore likely that the pathological
complications of diabetes are multifactorial and that hyperglyce-
mia in combination with other factors may be involved in their
initiation. In diabetic nephropathy, as in other renal diseases,
decline in renal function is best predicted by the severity of
interstitial fibrosis [6—8]. An understanding of the mechanisms
that initiate renal interstitial fibrosis in diabetes mellitus is there-
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fore important if therapeutic measures to prevent progression of
diabetic nephropathy are to be found.
Transforming growth factor-/Il (TGF-J31) is a multifunctional
cytokine that plays critical roles in modulating cell proliferation,
differentiation and the regulation of extracellular matrix turnover
[9—16]. A primary effect of TGF-131 is to promote the increased
synthesis of extracellular matrix components, and the inhibition of
matrix degradation [17].
We have previously demonstrated that exposure of human
renal proximal tubular cells (HPTC) in vitro to elevated D-glucose
concentrations resulted in the induction of TGF-131 mRNA in the
absence of TGF-/Ii protein synthesis [18]. However, TGF-/I1
protein synthesis and release was stimulated by the subsequent
addition of platelet-derived growth factor (PDGF) to the cells.
The mechanism of this effect appears to be related to the ability of
PDGF to alter the stability of TGF-/I1 mRNA induced by
elevated D-glucose concentration, thereby facilitating its transla-
tion [19]. In addition elevated D-glucose has been implicated in
the pathogenesis of glomerular changes associated with diabetic
nephropathy by induction of TGF-131 production [20, 21]
In the context of diabetic nephropathy, in vivo studies on
streptozotocin-induced diabetic rats have demonstrated promi-
nent glomerular macrophage infiltration that is associated with an
increased expression of TGF-pl [221. Furthermore, studies of
renal biopsies taken from patients with non-insulin dependent
diabetes mellitus have suggested that macrophages are involved in
the initiation of the pathological changes of diabetic nephropathy
[231. In addition in other cell systems IL-ill has been shown to
induce the synthesis of TGF-f31 [24].
It is possible the hyperglycemic conditions have a priming effect
on HPTC such that their responses to a variety of cytokines and
growth factors are amplified. The aim of the present study was
therefore to examine the role of the major macrophage derived
pro-inflammatory cytokines, IL-i/I and TNFa, in the control of
TGF-13i mRNA and protein synthesis by HPTC under conditions
of normal and elevated D-glucose concentrations. Our data
demonstrate that neither IL-i/I nor TNFa lead to an increase in
HPTC TGF-/I1 protein secretion despite the induction of TGF-/31
mRNA by both stimuli. Stimulation of HPTC pre-exposed to 25
mM D-glucose for 48 hours with IL-i/I but not TNFa lead to an
increased synthesis and release of latent TGF-/I1. The data
indicate that this response is related to the specific action of IL-i/I
on D-glucose induced TGF-pl mRNA.
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Methods
Cell culture
HPTC were isolated and characterized as previously described
[181. Briefly, small fragments of human renal cortical tissue
obtained from nephrectomy specimens were passed through a
series of mesh sieves, and proximal tubular cells recovered from
material retained on a 53-tim pore size sieve. The collected
material was digested with collagenase (750 U/mI) for 10 minutes,
and tubular cells isolated by centrifugation. Growth medium for
primary and subsequent cultures comprised a 1:1 mixture of
DMEM/Ham's F12 with 10% FCS supplemented with insulin (5
jig/mI), transferrin (5 jig/mI), selenium (5 ng/ml), and hydrocor-
tisone (40 ng/ml). (Culture media and supplements were obtained
from Life Technologies Ltd, Paisley, Scotland, UK) Cells were
grown at 37°C in 5% CO2 and 95% air. HPTC were characterized
to be of proximal tubular origin by enzyme histochemistry and
immunofluorescence. Cells stained positively for alkaline phos-
phatase, acid phosphatase, non-specific esterase, and glucose-6-
phosphatase, a pattern which is specific for proximal tubular
epithelial cells [251. In addition cells were positive for cytokeratin
and negative for Tamm-Horsfall glycoprotein. Electron micros-
copy demonstrated the presence of a rudimentary brush border.
We have previously demonstrated the viability of HPTC in
serum-free media for times up to 10 days [18]. All experiments
were performed under serum free conditions following a "growth
arrest" period of 72 hours in serum free medium. In all experi-
ments cells were used only up to the third passage.
RNA isolation, reverse transcription (RT), and polymerase chain
reaction (PCR) amplification
To study the kinetics of the IL- or TNFa mediated effects on
TGF-f31 gene expression, growth arrested HPTC were stimulated
by IL-lp (1 nglml) or TNFa (1 ng/ml) for time periods up to six
hours in serum free medium. At the defined time periods total
cellular RNA was extracted from both control and stimulated cells
following lysis with 4 M guanidine isothiocyanate and centrifuga-
tion through 5.7 M caesium chloride in 0.1 at EDTA [26]. Total
RNA was reverse transcribed to cDNA with MMLVTM reverse
transcriptase (Gihco Life Technologies Ltd, Paisley, UK), using
the random hexamers method as previously described [27].
Briefly, the reaction mixture contained I pl random hexamers
(100 tiM, Pharmacia Biosystems Ltd, Milton Keynes, UK), 5 jid
NTP's (2.5 mat, Gibco/BRL Life Technologies, Ltd), 2 j.tl lOx
PCR buffer (100 mat Tris/HC1, 500 mat KCI, 15 mat MgCl2 and
0.01% wt/vol gelatin), 2 jil Dlii (0.1 M, Gibco/BRL Life Tech-
nologies, Ltd), 1 j.d RNAase inhibitor (Promega, Southampton,
UK), 1 jil MMLVTM Superscript reverse transcriptasc (200
Units, Gibco/BRL Life Technologies, Ltd) and 1 jig of total RNA.
PCR amplification was performed in a total volume of 50 .d (2
jil of reverse transcription product and 48 j.d of master mix (36.25
p.I H20, 1.25 j.d 5'-primer (20 jiM), 1.25 1d 3'-primer (20 jiM), 4 jil
NTP's, 5 pA lOx PCR buffer and 0.25 ,id Taq polymerase (2.5 U;
Amplitaq© ILS Ltd, London, UK) using a Perkin Elmer 480
Thermocycler (Applied Biosystems Ltd, Warrington, UK). The
PCR protocol for TGF-pl mRNA and a-actin was as follows: first
cycle, 72°C for 10 minutes; second cycle, 94°C for three minutes
and 55°C for one minute, 72°C for one minute; third to 38th
cycles, 94°C for 40 seconds, 55°C for one minute, 72°C for one
minute. The final cycle was 94°C for one minute and 60°C for 10
Table 1. Sequences of the amplification primers
Product
Gene Primers size Reference
TGF-flI 5'-GGCAGTGGI1I'GAGCCGTGGA-3' 510 bp
5'-TGTTGGACAGCTGCTCCACCT-3'
a-Actin 5'-CCTTCCTGGGCATGGAGTCCT-3' 204 bp
5 '-GGAGCAATGATCYFGATCTF-3'
[281
[29]
minutes. PCR was performed for various cycles (between 30 and
35).
One-tenth of the PCR reaction from both test and control
(c-actin) product were mixed and separated by flat bed electro-
phoresis in 3% wt/vol NuSieve GTG agarose gels (Flowgen
Instruments Ltd, Sittingbourne, UK), stained with ethidium bro-
mide (Sigma) and photographed. The negatives were scanned
using a densitometer (Model 620 video densitometer, Bio-Rad
Laboratories Ltd) and the density of the bands compared to those
of the housekeeping gene. Results were expressed as TGF-1 to
a-actin ratios normalized to the first time point/dose of each
experiment. The sequences of the amplification primers are
shown in Table 1.
Determination of TGF-/31 protein secretion
To correlate the effect of IL-1/3 or TNFc on TGF-j31 gene
expression and protein secretion TGF-f31 was quantitated by
specific ELISA as previously described [30]. Subsequently, in
order to determine the modifying influence of elevated glucose
concentrations, cells were pre-exposed to 5 m or 25 mat D-
glucose prior to stimulation with either IL-113 or TNFs (1 ng/ml)
for up to 24 hours.
The ELISA used was an antibody capture enzyme linked
immunoassay specific for TGF-131 [26]. The assay is sensitive to
0.2 ng/ml with a range up to 100 ng/ml. The assay detects the
active 25 kDa human TGF-f31. Active TGF-pl is measured
directly, and latent TGF-pl can be measured indirectly following
acid activation of samples. All supernatant samples were assayed
before, and after acid activation to determine the amount of active
or latent TGF-[31 secretion respectively. Inter-assay precision
ranged from 4.3 to 9.6% (CV) and intra-assay precision ranged
from 2.8 to 8.6% (CV). There is no detectable cross reactivity with
a range of other cytokines and growth factors, including TGF-f32
and TGF-3. Results of TGF-pI protein secretion were expressed
as ng TGF-131/106 cells.
Assessment of TGF-f31 mRNA stability
The rate of degradation of TGF-/31 mRNA following the
addition of actinomycin D was used to assess the inherent stability
of mRNA induced by exposure of HPTC to 25 mat D-glucose.
Toxicity of actinomycin D was assessed using cellular ATP
measurements and the maximal non-toxic dose used (0.5 jig/mI)
[181. Growth arrested HPTC were incubated with 25 mat D-
glucose for 48 hours prior to removing the supernatant and adding
actinomycin D. The rate of mRNA degradation was determined
by isolating total cellular RNA at time points up to 12 hours after
the addition of actinomycin-D, and performing RT-PCR.
Post-transcriptional modification is known to be involved in the
control of TGF-131 protein synthesis, we therefore studied the
ability of IL-I or TNFa to modify the stability of glucose induced
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TGF-J31 mRNA. TGF-J31 mRNA was induced by treatment of
HPTC with 25 mi D-glucose for 48 hours. Transcription was then
inhibited by the addition of actinomycin-D, and cells stimulated
with IL-113 or TNFa (both at 1 ng/ml). The rate of mRNA
degradation was subsequently determined as described above.
Quantitation of TGF-131 mRNA was performed using the PCR
MIMIC system (Clontech Laboratories mc, Cambridge Bio-
Science, Cambridge, UK). TGF-f31 composite primers were de-
signed which amplified a 342 bp fragment of the BamHIIEcoR I
fragment of v-erbB DNA. The primary PCR amplification, using
the composite primers and the secondary PCR amplification with
the TGF-131 gene specific primers were performed for 30 cycles
according to the manufacturers protocol. The TGF-f31 PCR
MIMIC cDNA was purified with WizardTM PCR Preps DNA
Purification System (Promega Ltd) and the concentration of the
purified product was measured at 0D260 nm. A 10-fold TGF-131-
PCR MIMIC dilution series was set up and standard curves were
constructed for each sample of target eDNA to be measured. For
each sample, 2 1d target eDNA was included in each PCR reaction
mix together with 2 jil of one of the dilutions from the PCR
MIMIC dilution series. The PCR reaction was carried out accord-
ing to the normal protocol for the TGF-/31 specific primers. From
the standard curve generated in this manner the dilution at which
the experimental eDNA and the PCR MIMIC eDNA reached
equivalence was ascertained for each sample [311. The minimum
concentration of mRNA in the original extracted sample was then
calculated. The sequences of the amplification primers for quan-
titative PCR are shown in Table 2.
Statistics
For each individual experiment the mean of duplicate determi-
nations was calculated. The data are presented as means SEM of
n experiments. Statistical analysis between two groups was per-
formed using the unpaired Student's t-test, with a value of P <
0.05 considered to represent a significant difference.
Results
EJfrcts of IL-I 13 or TNFa on TGF-f31 gene expression and protein
production
TGF-131 mRNA expression. Stimulation of HPTC with IL-113 (1
ng/ml) resulted in a time dependent increase in the expression of
TGF-l31 mRNA that was first detectable after 60 minutes (Fig. 1).
After six hours, the TGF-/31!a-actin mRNA ratio was 1.6 times
that of the unslimulated control ratio. TNFa (1 ng/mI) stimulation
resulted in detectable TGF-/31 mRNA by 15 minutes; this in-
creased in a time dependent manner to a plateau by 60 minutes
(Fig. 2). At this time point there was a 1.85-fold increase in the
TGF-131/cs-actin mRNA ratio over control. Quantitative RT-PCR
revealed that following six hours stimulation with either IL-113 or
TNFa (both at 1 ng/ml) there was an increase over control, but no
difference in amount of TGF-p1 mRNA induced by these two
stimuli (14.8 5.6 vs. 19.7 4.9 pM).
TGF-131 secretion. In contrast to the increases in gene expres-
sion seen in response to stimulation with either IL-113 or TNFa,
there was no detectable increase in the secretion of active or
latent TGF-131 as assessed by specific ELISA of cell culture
supernatants from HPTC exposed to doses up to 10 ng/ml of
either IL-1p or TNFa.
The 25 mxt D-glucose priming of HPTC. Pre-incubation of
growth arrested HPTC with 25 mt D-glucose for 48 hours,
however, followed by stimulation with 1 ng/ml IL-1j3 resulted in a
time dependent secretion of latent TGF-/31 protein. This effect
was significant by four hours (8.7 1.76 ngIlO6 cells, mean SEM
N = 3, P = 0.04; Fig. 3A). The secretion of TGF-f31 was also dose
dependent, increasing from 3.5 0.249 M at 0.1 nglml to 14.6
1.89 M at 10 ng!ml (P = 0.005; Fig. 3B). Secreted TGF-/31 was
only detectable in any supernatant after in vitro acidification,
demonstrating that the TGF-f31 was secreted in its latent form.
HPTC pre-exposed to 25 mrvi D-glucose and subsequently
stimulated with TNFa did not secrete either active or latent
TGF-f31 irrespective of the dose of TNFa up to 10 nglml (Fig. 3).
Effect of inhibition of transcription and mRNA translation. Doses
of aetinomycin-D up to 250 nglml were added to confluent HPTC,
pre-exposed to 25 mrvi D-glucose. Inhibition of transcription by
actinomycin D had no effect on the amount of TGF-f31 secretion
following stimulation by 1 ng/ml IL-13 (Fig. 4). In contrast,
inhibition of mRNA translation by cyclohexamide resulted in a
dose dependent reduction of TGF-f31 secretion, following stimu-
lation by I nglml IL-1/3 (Fig. 4). Toxicity of actinomycin D and
cyclohexamide was assessed using cellular ATP measurements,
and only doses that did not lead to a reduction in cellular ATP or
lead to detachment of the cell monolayer were used.
TGF-p1 mRNA stability
Following induction of TGF-131 mRNA by exposure of HPTC
to 25 msi D-glucose, actinomycin-D was added to inhibit de novo
gene transcription. TGF-131 mRNA levels showed a steady decline
from 15.56 2.36 M to 3.21 1.96 M (mean SEM, N = 3, P =
0.007) 12 hours after addition of aetinomycin-D (Fig. 5). In
contrast, following the induction of TGF-131 mRNA by 25 mM
D-glucose, and inhibition of transcription by actinomycin-D for
one hour, quantitation of TGF-/31 mRNA revealed that the
amount of mRNA remained unchanged for up to 12 hours
following IL-1p stimulation (pre-actinomycin 13.5 1.7 prvi, 12 hr
post-IL-i/I, 12.9 1.9 p, mean SEM, N = 3, P = 0.4; Fig. 6B).
Quantitation of TGF-f31 mRNA following TNFa stimulation of
25 mvt D-glucose primed, actinomycin-D treated HPTC con-
firmed that TNF did not alter the rate of decline of TGF-/31
mRNA (pre-actinomycin D 57.3 3.8 prvi, 12 hr post-TNFa,
17.2 1.33 p, mean SEM, N = 3, P = 0.005; Fig. 6C). These
data indicate that IL-i/I, but not TNFc, increased the stability of
glucose induced TGF-/I1 mRNA.
Gene
Table 2. Sequences of the amplification primers for quantitative PCR
Primers
TGF-131 5 '-ACCGGCCF[TCCTGCTTCTCA-3'
S '-CGCCCGGG117ATGCTGGTTGT-3'
TGF-pl 5 '-ACCGGCCmCCTGCTFCTCA
Mimic CAGCCGTCCCAAGTITTCGTG-3
Product
size Reference
288 hp [281
5'-CGCCCGGGrFATGCTGGTTG
TGTGCCCCTGCCCATTTCTGT-3' 342 bp
(I)
8178615
c 492ii 369
246
a-
1)
Cd) 123
Cl)
-D
- 861
738
61C/) 49
. 369
246
123
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Discussion
The aim of the present study was to test the hypothesis that
D-glucose primes HPTC for subsequent TGF-131 synthesis follow-
ing the addition of pro-inflammatory macrophagc-derived cyto-
kines. This hypothesis was based on our previous observations
that exposure of HPTC to elevated D-glucose concentrations
induced TGF-131 gene expression, but not TGF-pl protein secre-
tion [18]. The addition of PDGF to D-glucose treated HPTC,
however, resulted in the synthesis and secretion of latent TGF-pl
protein. Under the same conditions stimulation with basic fibro-
blast growth factor (bFGF) of HPTC pre-treated with 25 mM
D-glucose did not prime for TGF-1 protein synthesis [32]. The
data presented in the present study demonstrate that exposure of
HPTC to either IL-1/3 or TNFa induced TGF-1 mRNA. Despite
increased TGF-pl gene expression, however, neither cytokine
induced TGF-/31 protein secretion. Stimulation with JL-1/3 of
HPTC pre-treated with 25 m'vi D-glucose, however, lead to the
secretion of latent TGF-pl that was both time and dose depen-
dent. There was no such effect of TNFa on HPTC pre-exposed to
25 mrvi D-glucose.
TGF-pl synthesis is regulated at the levels of transcription,
translation and secretion. Studies with monocytes have identified
a discordance between TGF-131 mRNA levels and the amount of
protein synthesized [331. Studies in human articular chondrocytes
have further highlighted differences in the level of control of
TGF-J31 synthesis. While bFGF promotes the release of TGF-pl,
it has no effect on steady-state TGF-131 mRNA levels. In contrast
PDGF up-regulates TGF-/3l mRNA as well as stimulates TGF-l
B
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Fig. 1. Time dependent induction of TGF-131 mRNA by IL-1 Growth arrested HPTC were stimulated with I ng/ml IL-1/3 for times up to six hours.
Following RT-PCR, TGF-pl and o-actin mRNA were separated by flat bed electrophoresis in 3% agarose gels (A) and the results expressed as the
densitometric ratios of TGF-pl mRNA to n-actin normalized for the unstimulated ratio (B). One representative experiment is shown (—RT = negative
control for reverse transcription, —PCR = negative control for polymerase chain reaction).
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Fig. 2. Time dependent induction of TGF-pl mRNA by TNFa Growth arrested HPTC were stimulated with 1 ng/ml TNFa for times up to six hours.
Following RT-PCR, TGF-pI and a-actin mRNA were separated by flat bed electrophoresis in 3% agarose gels (A) and the results expressed as the
densitometric ratios of TGF-/31 mRNA to cs-actin normalized for the unstimulated ratio (B). One representative experiment is shown.
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Fig. 3. Effect of ILI-13 and TNFa on TGF-pI secretion. Growth arrested
HPTC were pre-exposed to 25 mai D-glucose prior to stimulation with
either TNFa () or IL-13 (•). (A) Time dependent secretion of TGF-f31
following stimulation with I ng/ml of either TL-113 or TNFa. (B) Dose
dependent secretion of TGF-f3 following stimulation for 24 hours with
either IL-1 or TNFa. Data presented are the means SEM of TGF-1
release expressed as ng/106 cells from three separate experiments with
HPTC prepared from separate nephrectomy specimens, < 0.05.
protein secretion [34]. Therefore, even in the same cell type
TGF-f31 synthesis can be regulated at either the transcriptional or
post-transcriptional levels.
In the current study we have demonstrated that, although
TGF-pl mRNA was induced following exposure of HPTC to
either IL-l or TNF-a, neither stimulus alone was capable of
stimulating the synthesis of TGF-1 protein. By demonstrating
that the IL-113 induced TGF-pl secretion in glucose primed
HPTC was inhibited by cyclohexamide but not actinomycin D, we
have demonstrated that IL-lp increased TGF-J31 translation
independently of its stimulatory effect on TGF-131 gene expres-
sion. Furthermore, we have demonstrated, by using actinomy-
cin-D chase experiments and quantitative RT-PCR, that IL-1j3
0 0.05 0.01 0.1 2.5
Cyclohexamide, .tg/m/
Fig. 4. Inhibition of IL-113 stimulated TGF-/31 secretion by cyclohexamide.
Growth arrested HPTC were pre-exposed to 25 mai D-glucose for 48
hours prior to addition of increasing doses of either actinomycin-D (0 to
250ng/ml) or cyelohexamide (0 to 5 xg/ml). Following incubation for one
hour, the cells were washed with phosphate buffered saline pH 7.3 (PBS)
and subsequently stimulated with IL-lp (I ng/ml) for a further 24 hours
following which TGF-f31 was quantitated. Data presented are the
means SEM of TGF-I release expressed as ng/10' cells from three
separate experiments with HPTC prepared from separate nephrectomy
specimens, *p < 0.05.
increased the stability of the TGF-131 mRNA induced by D-
glucose. Following this stabilization, TGF-pl mRNA was trans-
lated and latent TGF-f31 secreted by the cells. In contrast, TNFx
had no effect on the stability of D-glucose induced TGF-1
mRNA, and did not initiate its translation. This effect of IL-lp is
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Fig. 5. Stability of 25 mM D-glucose induced
TGF-j31 mRNA. Following induction of TGF-
131 mRNA by application of 25 mrvi D-glucosc
to growth arrested HPTC for 48 hours,
transcription was inhibited by the addition of
actinomycin-D (5 sg/ml). A. Total cellular RNA
isolated over the following 12 hours. Symbols
are: (1' ) RNA extraction; (fl) actinomycin-D
treatment. B. Stability of TGF-131 mRNA was
determined by both quantitative mimic PCR
(graph) and by conventional RT-PCR (gel
insert). Following conventional RT-PCR, TGF-
[31 and a-actin mRNA were separated by flat
bed electrophoresis in 3% agarose gels. Data
represent mean SEM, *P < 0.05.
analogous to our previously published observations that demon-
strated secretion of TGF-!31 following the stabilization of D-
glucose induced TGF-p1 mRNA by the application of PDGF.
Stabilization of D-glucose induced TGF-f31 mRNA may thus
represent the common mechanism by which the application of a
second stimulus may lead to TGF-f31 protein synthesis in D-
glucose primed HPTC.
It is interesting to speculate on possible mechanisms by which
the addition of a second stimulus may alter the stability of
D-glucose induced TGF-131 mRNA and hence facilitate its trans-
lation in HPTC. Possible explanations include conformational
changes in the tertiary structure of the mRNA, or alteration of the
physical properties of the mRNA by protein binding induced by a
second stimulus. Although no cytosolic binding proteins have
been found that specifically regulate translation of TGF-p1
mRNA, two untranslated regions of its mRNA have been postu-
lated to be involved in its post-transcriptional control, and hence
might be the targets for IL-1[3 or PDGF action. Analysis of the
sequence of D-glucose induced TGF-j31 mRNA has identified an
adenosine-uridine (AU)-rich region in its 3' untranslated region
that targets mRNA for rapid cytosolic degradation [28]. Cytosolic
proteins have been identified that hind to this motif, and it has
been shown that these proteins may be up-regulated by stimuli
such as phorbol esters and/or calcium ionophore [35, 361.
Recently another untranslated region at the 5' end of TGF-/31
mRNA has been demonstrated to be involved in the post-
transcriptional control of TGF-p1 synthesis [37]. This sequence
contains an unusually long untranslated region, with a high GC
content. When inserted into the 5' untranslated region for human
growth hormone it inhibits its production. Computer analysis has
shown that this 5' untranslated region contains a stable secondary
stem-loop structure. It is thought that duplex structures such as
this, positioned close to the 5' end of mRNA, inhibit the initiation
of translation by preventing binding of a 40S ribosomal subunit.
Secondary structures present in the 5' untranslated region may
serve as binding sites for cytoplasmic proteins that are able to
modify its effect on the initiation of translation. Both of these
untranslated regions of TGF-/31 mRNA may therefore be poten-
tial sites for IL-1/3 action leading to increased TGF-131 mRNA
stability.
In summary, we have demonstrated that elevated concentra-
tions of D-glucose prime FIPTC for TGF-1 synthesis following
IL-1/3, but not TNFa, stimulation. Furthermore, we have shown
that IL-1/3, but not TNFx altered the stability of the D-glucose
25 mM D-glucose Actinomycin D
Rest cells
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Fig. 6. Effect of TNFa or IL-1f3 on D-glucose
induced TGF-/31 mRNA. Following the
induction of TGF-131 mRNA by application of
25 mti D-glucose to growth arrested HPTC for
48 hours, transcription was inhibited by the
addition of actinomyein-D (5 j.LgIml). Cells were
subsequently stimulated by TNFa (B) or lL-1
(C), and total cellular RNA isolated over the
following 12 hours (A). Symbols in A are: (t)
RNA extraction; (2) actinomycin-D treatment;() IL-1f3/TNFa treatment. Alteration in the
stability of D-glucose induced TGF-/31 mRNA
was determined by both quantitative mimic
PCR and by conventional RT-PCR (B and C).
Following conventional RT-PCR, TGF-/3l and
a-aetin mRNA were separated by flat bed
clectrophoresis in 3% agarose gels. Data
represents mean SEM, *P < 0.05)
induced TGF-pl mRNA. This was associated with the translation
of this TGF-131 transcript. Glomerular macrophage infiltration
has been implicated in the pathogenesis of a number of models of
progressive glomeruloscierosis, including the anti-thymocyte se-
rum and remnant kidney models [38, 3I. More recently a
prominent macrophage infiltration has been described in renal
biopsy specimens from patients with diabetic nephropathy [231, as
well as in the kidneys of streptozotocin treated rats [22]. Tn the
latter, macrophage infiltration was associated with increased
TGF-131 mRNA, and it was suggested that this process may be
involved in the pathological changes associated with diabetic
nephropathy. These infiltrating cells may therefore be a source of
pro-inflammatory cytokines which act upon resident cells.
It is clear that understanding the mechanisms that are involved
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in the initiation of interstitial fibrosis in diabetic nephropathy are
of great importance. As only 30% of all diabetic patients develop
diabetic nephropathy, it is recognized that its pathogenesis is
multifactorial in etiology, rather than the sole result of hypergly-
cemia. The data presented in this paper together with our
previous observations provide evidence that renal proximal tubu-
lar epithelial cells, in addition to their role in the control of fluid
and electrolyte balance, may contribute to the initiation of
pathological events in diseases such as diabetes by synthesizing
TGF-f31 through complex interactions involving D-glucose and
cytokines, such as PDGF and IL-1/3. Specifically, these findings
suggest that elevated glucose concentrations alone may be insuf-
ficient to initiate pathological changes, but may prime the kidney
for enhanced responses when exposed to other insults. Thus in the
presence of elevated concentrations of glucose, inflammation
and/or infection might be expected to have a greater impact than
when they occur during euglycemia.
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